Advertisement

Topics

Dutch Biotech could treat Dyslipidemia with Belgian Nanobody

05:24 EDT 23 Aug 2017 | Labiotech.eu

Argenx’ partner Staten Biotechnology has published results that present a drug licensed from the Belgian biotech as a promising approach to control blood lipid levels. Staten Biotechnology is a young biotech in Breda, the Netherlands, focusing on treating dyslipidemia and ...

This awesome article Dutch Biotech could treat Dyslipidemia with Belgian Nanobody appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Dutch Biotech could treat Dyslipidemia with Belgian Nanobody

NEXT ARTICLE

More From BioPortfolio on "Dutch Biotech could treat Dyslipidemia with Belgian Nanobody"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...